Modulating the expression of NLRP3 inflammasome by MAEO suggests that inhibiting its activity could be a potential therapeutic strategy for treating inflammatory skin disorders such as psoriasis and eczema. This evidence concerns the gene NLRP3 and Eczematoid dermatitis.